Cargando…

Targeting tumor-stroma communication by blocking endothelin-1 receptors sensitizes high-grade serous ovarian cancer to PARP inhibition

PARP inhibitors (PARPi) have changed the treatment paradigm of high-grade serous ovarian cancer (HG-SOC). However, the impact of this class of inhibitors in HG-SOC patients with a high rate of TP53 mutations is limited, highlighting the need to develop combinatorial therapeutic strategies to improve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tocci, Piera, Roman, Celia, Sestito, Rosanna, Di Castro, Valeriana, Sacconi, Andrea, Molineris, Ivan, Paolini, Francesca, Carosi, Mariantonia, Tonon, Giovanni, Blandino, Giovanni, Bagnato, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816119/ https://www.ncbi.nlm.nih.gov/pubmed/36604418 http://dx.doi.org/10.1038/s41419-022-05538-6

Ejemplares similares

Functional interaction between endothelin-1 and ZEB1/YAP signaling regulates cellular plasticity and metastasis in high-grade serous ovarian cancer
por: Sestito, Rosanna, et al.
Publicado: (2022)

β-arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer
por: Tocci, Piera, et al.
Publicado: (2019)

Targeting endothelin 1 receptor-miR-200b/c-ZEB1 circuitry blunts metastatic progression in ovarian cancer
por: Sestito, Rosanna, et al.
Publicado: (2020)

miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma
por: Sestito, Rosanna, et al.
Publicado: (2015)

YAP and endothelin-1 signaling: an emerging alliance in cancer
por: Tocci, Piera, et al.
Publicado: (2021)

Nuclear β-arrestin1 is a critical cofactor of hypoxia-inducible factor-1α signaling in endothelin-1-induced ovarian tumor progression
por: Cianfrocca, Roberta, et al.
Publicado: (2016)

Blocking endothelin-1-receptor/β-catenin circuit sensitizes to chemotherapy in colorectal cancer
por: Cianfrocca, Roberta, et al.
Publicado: (2017)

hMENA is a key regulator in endothelin-1/β-arrestin1–induced invadopodial function and metastatic process
por: Di Modugno, Francesca, et al.
Publicado: (2018)

Targeting Endothelin-1 Receptor/β-Arrestin-1 Axis in Ovarian Cancer: From Basic Research to a Therapeutic Approach
por: Tocci, Piera, et al.
Publicado: (2019)

Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer
por: Raspaglio, Giuseppina, et al.
Publicado: (2023)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Breast cancer metastasis: Is it a matter of OMICS and proper ex-vivo models?
por: Cioce, Mario, et al.
Publicado: (2022)

The interaction of β-arrestin1 with talin1 driven by endothelin A receptor as a feature of α5β1 integrin activation in high-grade serous ovarian cancer
por: Masi, Ilenia, et al.
Publicado: (2023)

Endothelin-1 Inhibits Prolyl Hydroxylase Domain 2 to Activate Hypoxia-Inducible Factor-1α in Melanoma Cells
por: Spinella, Francesca, et al.
Publicado: (2010)

Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer
por: Sahin, Irem Durmaz, et al.
Publicado: (2019)

Disrupting the endothelin and Wnt relationship to overcome chemoresistance
por: Rosanò, Laura, et al.
Publicado: (2015)

PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer
por: Dickson, Kristie-Ann, et al.
Publicado: (2021)

Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells
por: Jia, Yaxun, et al.
Publicado: (2022)

Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system
por: Bound, Nirashaa T., et al.
Publicado: (2022)

Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
por: Vendrell, Julie A., et al.
Publicado: (2023)

Endothelin receptors as novel targets in tumor therapy
por: Bagnato, Anna, et al.
Publicado: (2004)

Epigenetic silencing of miR-296 and miR-512 ensures hTERT dependent apoptosis protection and telomere maintenance in basal-type breast cancer cells
por: Dinami, Roberto, et al.
Publicado: (2017)

Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
por: Kanakkanthara, Arun, et al.
Publicado: (2022)

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
por: Lu, Xue, et al.
Publicado: (2022)

High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma
por: Jank, Paul, et al.
Publicado: (2023)

Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP
por: Yokoyama, Takuhei, et al.
Publicado: (2017)

β-arrestin1 at the cross-road of endothelin-1 signaling in cancer
por: Rosanò, Laura, et al.
Publicado: (2016)

Identification of novel COX-2 / CYP19A1 axis involved in the mesothelioma pathogenesis opens new therapeutic opportunities
por: Nuvoli, Barbara, et al.
Publicado: (2021)

Correction: Identification of novel COX-2 / CYP19A1 axis involved in the mesothelioma pathogenesis opens new therapeutic opportunities
por: Nuvoli, Barbara, et al.
Publicado: (2023)

HSF-1/miR-145-5p transcriptional axis enhances hyperthermic intraperitoneal chemotherapy efficacy on peritoneal ovarian carcinosis
por: Di Agostino, Silvia, et al.
Publicado: (2023)

Genome-wide analysis of microRNA to evaluate prognostic markers in isolated cancer glands and surrounding stroma in high-grade serous ovarian carcinoma
por: Sato, Chie, et al.
Publicado: (2020)

Computational tumor stroma reaction evaluation led to novel prognosis-associated fibrosis and molecular signature discoveries in high-grade serous ovarian carcinoma
por: Jiang, Jun, et al.
Publicado: (2022)

Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification
por: Gasimli, Khayal, et al.
Publicado: (2022)

A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions
por: Donzelli, Sara, et al.
Publicado: (2022)

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines
por: Fleury, Hubert, et al.
Publicado: (2016)

Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance
por: Hurley, Rachel M, et al.
Publicado: (2021)

miR-181c associates with tumor relapse of high grade osteosarcoma
por: Federica, Mori, et al.
Publicado: (2015)

Concurrent Primary Peritoneal Low-Grade Serous Carcinoma and Endometrial High-Grade Serous Carcinoma
por: Lockyer, Megan G., et al.
Publicado: (2015)

Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells
por: Gomez, Miriam K., et al.
Publicado: (2020)

Invasive bilateral breast cancer and high grade serous ovarian cancer with BRCA1-germline mutation and brainstem metastasis under PARP inhibitors
por: Zahari, Mihaela Mărioara, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vl5o6rcddm129u366bss5dmq4g